Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Front Bioeng Biotechnol ; 10: 803218, 2022.
Article in English | MEDLINE | ID: mdl-35265594

ABSTRACT

Psoriasis (PS) and Atopic Dermatitis (AD) are two of the most prevalent inflammatory skin diseases. Dysregulations in the immune response are believed to play a crucial role in the pathogenesis of these conditions. Various parallels can be drawn between the two disorders, as they are both genetically mediated, and characterised by dry, scaly skin caused by abnormal proliferation of epidermal keratinocytes. The use of in vitro disease models has become an increasingly popular method to study PS and AD due to the high reproducibility and accuracy in recapitulating the pathogenesis of these conditions. However, due to the extensive range of in vitro models available and the majority of these being at early stages of production, areas of development are needed. This review summarises the key features of PS and AD, the different types of in vitro models available to study their pathophysiology and evaluating their efficacy in addition to discussing future research opportunities.

2.
Cells ; 11(2)2022 01 11.
Article in English | MEDLINE | ID: mdl-35053343

ABSTRACT

Formyl peptide receptors (Fprs) are a G-protein-coupled receptor family mainly expressed on leukocytes. The activation of Fpr1 and Fpr2 triggers a cascade of signaling events, leading to leukocyte migration, cytokine release, and increased phagocytosis. In this study, we evaluate the effects of the Fpr1 and Fpr2 agonists Ac9-12 and WKYMV, respectively, in carrageenan-induced acute peritonitis and LPS-stimulated macrophages. Peritonitis was induced in male C57BL/6 mice through the intraperitoneal injection of 1 mL of 3% carrageenan solution or saline (control). Pre-treatments with Ac9-12 and WKYMV reduced leukocyte influx to the peritoneal cavity, particularly neutrophils and monocytes, and the release of IL-1ß. The addition of the Fpr2 antagonist WRW4 reversed only the anti-inflammatory actions of WKYMV. In vitro, the administration of Boc2 and WRW4 reversed the effects of Ac9-12 and WKYMV, respectively, in the production of IL-6 by LPS-stimulated macrophages. These biological effects of peptides were differently regulated by ERK and p38 signaling pathways. Lipidomic analysis evidenced that Ac9-12 and WKYMV altered the intracellular lipid profile of LPS-stimulated macrophages, revealing an increased concentration of several glycerophospholipids, suggesting regulation of inflammatory pathways triggered by LPS. Overall, our data indicate the therapeutic potential of Ac9-12 and WKYMV via Fpr1 or Fpr2-activation in the inflammatory response and macrophage activation.


Subject(s)
Inflammation/pathology , Oligopeptides/pharmacology , Peptides/pharmacology , Receptors, Formyl Peptide/agonists , Animals , Cell Movement/drug effects , Cytokines/metabolism , Disease Models, Animal , Interleukin-1beta/metabolism , Leukocytes/cytology , Leukocytes/drug effects , Lipidomics , Lipopolysaccharides/pharmacology , Macrophage Activation/drug effects , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Peritonitis/pathology , RAW 264.7 Cells , Receptors, Formyl Peptide/metabolism
3.
Inflammation ; 45(3): 1133-1145, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35031944

ABSTRACT

The pathogenesis of atopic dermatitis (AD) and psoriasis (Ps) overlaps, particularly the activation of the immune response and tissue damage. Here, we evaluated galectin (Gal)-1 and Gal-3 levels, which are beta-galactoside-binding proteins with immunomodulatory functions and examined their effects on human keratinocytes stimulated with either interleukin (IL)-4 or IL-17A. Skin biopsies from AD, Ps, and control patients were evaluated using histological and immunohistochemical analyses. Six studies containing publicly available transcriptome data were individually analyzed using the GEO2R tool to detect Gal-1 and Gal-3 mRNA levels. In vitro, IL-4- or IL-17A-stimulated keratinocytes were treated with or without Gal-1 or Gal-3 to evaluate cytokine release and migration. Our findings showed different patterns of expression for Gal-1 and Gal-3 in AD and Ps skins. Densitometric analysis in skin samples showed a marked increase in the protein Gal-1 levels in Ps epidermis and in both AD and Ps dermis compared to controls. Protein and mRNA Gal-3 levels were downregulated in AD and Ps lesional skin compared with the control samples. In vitro, both galectins addition abrogated the release of IL-8 and RANTES in IL-17-stimulated keratinocytes after 24 h, whereas IL-6 release was downregulated by Gal-3 and Gal-1 in IL-4- and IL-17-stimulated cells, respectively. Administration of both galectins also increased the rate of keratinocyte migration under IL-4 or IL-17 stimulation conditions compared with untreated cells. Altogether, the immunoregulatory and migration effects of Gal-1 and Gal-3 on keratinocytes under inflammatory microenvironment make them interesting targets for future therapies in cutaneous diseases.


Subject(s)
Dermatitis, Atopic , Psoriasis , Blood Proteins , Cells, Cultured , Galectin 1/metabolism , Galectin 1/pharmacology , Galectin 3/metabolism , Galectin 3/pharmacology , Galectins , Humans , Immunity , Interleukin-17/metabolism , Interleukin-4/metabolism , Interleukin-4/pharmacology , Keratinocytes/metabolism , Psoriasis/metabolism , RNA, Messenger/metabolism
4.
J Photochem Photobiol B ; 221: 112247, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34175580

ABSTRACT

A need exists for further research elucidating the benefits of environmentally safe photoprotective agents against ultraviolet (UV) exposure, and plant extracts represent a human-friendly alternative formulation. This study was designed to evaluate the potential use of Bellis perennis extract (BPE), from the Asteraceae family, known as the common daisy or the English daisy, in cosmeceuticals as a photoprotective factor, using an in vitro model of UVA-induced keratinocyte damage. Human skin keratinocytes (HaCaT cell line) were incubated with BPE at 0.01, 0.1, or 1% in Dulbecco's Modified Eagle Medium (DMEM), and after 15 min they were submitted to UVA radiation at 5, 10, and 15 J/cm2 doses, respectively. For comparative purposes, Polypodium leucotomos extract (PLE), known as the fern, was used as a positive control in assessing the photoprotective effect. After 24 h of UVA exposure, cell viability (MTT and LDH assays), levels of cleaved caspase-3, cyclooxygenase-2, IL-6, reactive oxygen species (ROS) and antioxidant enzyme (catalase, SOD, and glutathione peroxidase) activity were determined. UVA radiation at 5, 10, and 15 J/cm2 doses reduced cell viability to 63%, 43%, and 23%, respectively; we selected 10 J/cm2 for our purposes. After 24 h of UVA exposure, treatment with 1% BPE and 1% PLE significantly recovered cell viability (p < 0.05). Furthermore, treatment was associated with lower cleaved caspase-3 and ROS levels, higher catalase activity, and lower IL-6 levels in the treated UVA keratinocytes compared with the untreated UVA group (p < 0.01). Our results demonstrate photoprotective and immunomodulatory effects of BPE in skin keratinocytes and support its use as a bioactive agent in cosmetic formulations to prevent skin damage caused by exposure to the UV light.


Subject(s)
Asteraceae/chemistry , Immunomodulation/drug effects , Plant Extracts/pharmacology , Radiation-Protective Agents/pharmacology , Ultraviolet Rays , Asteraceae/metabolism , Caspase 3/metabolism , Catalase/metabolism , Cell Line , Cell Survival/drug effects , Cell Survival/radiation effects , Humans , Immunomodulation/radiation effects , Keratinocytes/cytology , Keratinocytes/metabolism , Plant Extracts/chemistry , Radiation-Protective Agents/chemistry , Reactive Oxygen Species/metabolism
5.
Cells ; 10(4)2021 04 20.
Article in English | MEDLINE | ID: mdl-33923930

ABSTRACT

Galectin-9 (Gal-9) is a beta-galactoside-binding protein with a variety of biological functions related to immune response. However, in allergic diseases, its mechanism of action is not fully understood. This study evaluates the expression pattern of Gal-9 in patients with atopic dermatitis (AD), in ovalbumin (OVA)-induced experimental atopic dermatitis (AD) in mice, as well as its effect on human keratinocytes. The skin of OVA-immunized BALB/c mice was challenged with drops containing OVA on days 11, 14-18, and 21-24. HaCaT cells were cultured in the following experimental conditions: control (growth medium only) or stimulated with TNF-α/IFN-γ, or IL-4, or IL-17 with or without Gal-9 treatment. AD was characterized by increased levels of Gal-9 in mouse and human skin, especially in the epidermis, and with a marked influx of Gal-9 positive eosinophils and mast cells compared to the control group. Gal-9 showed an immunomodulatory effect on keratinocytes by decreasing the release of IL-6 by IL-4-stimulated keratinocytes or increasing the IL-6 and RANTES levels by IL-17- or TNF-α/IFN-γ-stimulated cells, respectively. Under IL-17, Gal-9 treatment also altered the proliferation rate of cells. Overall, increased levels of Gal-9 in AD skin contribute to the control of inflammatory response and the proliferative process of keratinocytes, suggesting this lectin as a relevant therapeutic target.


Subject(s)
Dermatitis, Atopic/metabolism , Dermatitis, Atopic/pathology , Galectins/metabolism , Keratinocytes/metabolism , Keratinocytes/pathology , Animals , Cell Movement , Cell Proliferation , Cytokines/metabolism , Disease Models, Animal , Humans , Inflammation/pathology , Male , Mice, Inbred BALB C , Skin/pathology , Up-Regulation/genetics
6.
Cells ; 8(1)2019 01 15.
Article in English | MEDLINE | ID: mdl-30650525

ABSTRACT

Annexin A1 (AnxA1) is a protein with potent anti-inflammatory actions and an interesting target that has been poorly explored in skin inflammation. This work evaluated the lack of endogenous AnxA1 in the progression of ovalbumin (OVA)-induced atopic dermatitis (AD)-like skin lesions. OVA/Alum-immunized C57BL/6 male wild-type (WT) and AnxA1 null (AnxA1-/-) mice were challenged with drops containing OVA on days 11, 14⁻18 and 21⁻24. The AnxA1-/- AD group exhibited skin with intense erythema, erosion and dryness associated with increased skin thickness compared to the AD WT group. The lack of endogenous AnxA1 also increased IgE relative to WT animals, demonstrating exacerbation of the allergic response. Histological analysis revealed intense eosinophilia and mast-cell activation in AD animals, especially in AnxA1-/-. Both AD groups increased skin interleukin (IL)-13 levels, while IL-17A was upregulated in AnxA1-/- lymph nodes and mast cells. High levels of phosphorylated ERK were detected in keratinocytes from AD groups. However, phospho-ERK levels were higher in the AnxA1-/- when compared to the respective control groups. Our results suggest AnxA1 as an important therapeutic target for inflammatory skin diseases.


Subject(s)
Annexin A1/physiology , Dermatitis, Atopic/immunology , Dermatitis, Atopic/pathology , Mast Cells/immunology , Animals , Annexin A1/genetics , Disease Models, Animal , Disease Progression , Immunoglobulin E/immunology , Interleukin-13/immunology , Interleukin-17/immunology , MAP Kinase Signaling System/immunology , Male , Mice , Mice, Inbred C57BL
7.
Br J Ophthalmol ; 102(7): 1003-1010, 2018 07.
Article in English | MEDLINE | ID: mdl-29502069

ABSTRACT

AIMS: To evaluate galectin-3 (Gal-3), a ß-galactoside binding protein, as a possible biomarker in ocular allergy and further investigated the role of endogenous Gal-3 in a murine model of ovalbumin (OVA)-induced allergic conjunctivitis (AC). METHODS: Conjunctival impression cytology specimens from control and patients with severe vernal keratoconjunctivitis, treated or untreated, were used to evaluate Gal-3 expression by immunocytochemistry. To investigate the mechanism of action of Gal-3, OVA-immunised BALB/c male wild-type (WT) and Gal-3 null (Gal-3-/-) mice were challenged with eye drops containing OVA on days 14-16 with a subset of animals pretreated with 0.03% tacrolimus (TC) or dexamethasone (Dex). RESULTS: Patients with AC and OVA-sensitised WT mice exhibited increased levels of Gal-3 in the conjunctiva compared with control, an effect reverted by the action of Dex and TC therapy. Twenty-four hours after the final OVA challenge, total and anti-OVA IgE levels increased significantly in the blood of OVA-sensitised WT and Gal-3-/- mice compared with controls, supporting the efficacy of the AC model. The lack of endogenous Gal-3 exacerbated the local inflammatory response, increasing the influx of eosinophils and mast cell activation. Additionally, OVA-sensitised Gal-3-/- animals exhibited increased CD4+ expression in the eyes as well as eotaxin, IL-4, IL-13 and interferon-γ levels in the tear fluid compared with WT animals. CONCLUSION: Gal-3 contributes to the pathogenesis of ocular allergy and represents a relevant therapeutic target.


Subject(s)
Biomarkers/metabolism , Conjunctivitis, Allergic/metabolism , Galectin 3/metabolism , Adolescent , Adult , Animals , Anti-Allergic Agents/therapeutic use , Blood Proteins , Blotting, Western , Child , Conjunctivitis, Allergic/chemically induced , Conjunctivitis, Allergic/diagnosis , Conjunctivitis, Allergic/drug therapy , Disease Models, Animal , Drug Therapy, Combination , Female , Galectins , Glucocorticoids/therapeutic use , Humans , Immunoenzyme Techniques , Immunoglobulin E/blood , Male , Mice , Mice, Inbred BALB C , Ovalbumin/toxicity , Tacrolimus/therapeutic use
8.
J Mol Med (Berl) ; 95(9): 1005-1015, 2017 09.
Article in English | MEDLINE | ID: mdl-28664215

ABSTRACT

Atopic dermatitis (AD) is caused by both dysregulated immune responses and an impaired skin barrier. Although beta-galactoside-binding protein galectin-1 (Gal-1) has immunomodulatory effects in several inflammatory disorders, therapeutic strategies based on its anti-inflammatory properties have not been explored in AD. Thus, we evaluate pharmacological treatment with Gal-1 in the progression of an ovalbumin (OVA)-induced AD-like skin lesions. The skin of OVA-immunized male BALB/c mice was challenged with drops containing OVA on days 11, 14-18 and 21-24. Additionally, in the last week, a subset of animals was treated intraperitoneally with recombinant Gal-1 (rGal-1) or dexamethasone (Dex). Treatment with rGal-1 decreased the clinical signs of dermatitis in BALB/c mice and diminished local eotaxin and IFN-γ levels. The treatment also suppressed the infiltration of eosinophils and mast cells, which was verified by reduced expression of mouse mast cell protease 6 (mMCP6) and eosinophil peroxidase (EPX). These localized effects are associated with extracellular signal-regulated kinase (ERK) activation and downregulation of endogenous Gal-1. The inhibition of disease progression induced by rGal-1 was also correlated with reduced plasma IL-17 levels. Our results demonstrate that rGal-1 is an effective treatment for allergic skin inflammation in AD and may impact the development of novel strategies for skin inflammatory diseases. KEY MESSAGES: Pharmacological treatment with rGal-1 reduces clinical signs of atopic dermatitis. Systemic treatment with rGal-1 inhibits eosinophil and mast cell influx in the skin of AD animals. rGal-1 reduced local eotaxin levels and systemic IL-17 levels. The inhibition of disease progression induced by rGal-1 was correlated with upregulation of phosphorylated ERK.


Subject(s)
Dermatitis, Atopic/metabolism , Galectin 1/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Biopsy , Cytokines/metabolism , Dermatitis, Atopic/immunology , Dermatitis, Atopic/pathology , Dermatitis, Atopic/therapy , Disease Models, Animal , Galectin 1/genetics , Galectin 1/pharmacology , Gene Expression , Immunity/drug effects , Immunoglobulin E/immunology , Immunomodulation/drug effects , Leukocyte Count , MAP Kinase Signaling System/drug effects , Male , Mice , Phenotype
9.
Anal Cell Pathol (Amst) ; 2015: 285708, 2015.
Article in English | MEDLINE | ID: mdl-26351625

ABSTRACT

Cancer pain directly affects the patient's quality of life. We have previously demonstrated that the subcutaneous administration of the mammary adenocarcinoma known as Ehrlich tumor induces pain in mice. Several studies have shown that the flavonoid quercetin presents important biological effects, including anti-inflammatory, antioxidant, analgesic, and antitumor activity. Therefore, the analgesic effect and mechanisms of quercetin were evaluated in Ehrlich tumor-induced cancer pain in mice. Intraperitoneal (i.p.) treatments with quercetin reduced Ehrlich tumor-induced mechanical and thermal hyperalgesia, but not paw thickness or histological alterations, indicating an analgesic effect without affecting tumor growth. Regarding the analgesic mechanisms of quercetin, it inhibited the production of hyperalgesic cytokines IL-1ß and TNFα and decreased neutrophil recruitment (myeloperoxidase activity) and oxidative stress. Naloxone (opioid receptor antagonist) inhibited quercetin analgesia without interfering with neutrophil recruitment, cytokine production, and oxidative stress. Importantly, cotreatment with morphine and quercetin at doses that were ineffective as single treatment reduced the nociceptive responses. Concluding, quercetin reduces the Ehrlich tumor-induced cancer pain by reducing the production of hyperalgesic cytokines, neutrophil recruitment, and oxidative stress as well as by activating an opioid-dependent analgesic pathway and potentiation of morphine analgesia. Thus, quercetin treatment seems a suitable therapeutic approach for cancer pain that merits further investigation.


Subject(s)
Carcinoma, Ehrlich Tumor/complications , Pain/drug therapy , Pain/etiology , Quercetin/therapeutic use , Analgesics/pharmacology , Analgesics/therapeutic use , Analgesics, Opioid/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Drug Therapy, Combination , Female , Interleukin-1beta/biosynthesis , Male , Mice , Morphine/pharmacology , Morphine/therapeutic use , Naloxone/pharmacology , Naloxone/therapeutic use , Neutrophil Infiltration/drug effects , Oxidative Stress , Pain/pathology , Quercetin/pharmacology , Skin/pathology , Spinal Cord/pathology , Tumor Necrosis Factor-alpha/biosynthesis
10.
Biomed Res Int ; 2013: 624815, 2013.
Article in English | MEDLINE | ID: mdl-24073414

ABSTRACT

The Ehrlich tumor is a mammary adenocarcinoma of mice that can be developed in solid and ascitic forms depending on its administration in tissues or cavities, respectively. The present study investigates whether the subcutaneous plantar administration of the Ehrlich tumor cells induces pain-like behavior and initial pharmacological susceptibility characteristics. The Ehrlich tumor cells (1 × 10(4)-10(7) cells) induced dose-dependent mechanical hyperalgesia (electronic version of the von Frey filaments), paw edema/tumor growth (caliper), and flinches compared with the saline group between days 2 and 12. There was no difference between doses of cells regarding thermal hyperalgesia in the hot-plate test. Indomethacin (a cyclooxygenase inhibitor) and amitriptyline hydrochloride (a tricyclic antidepressant) treatments did not affect flinches or thermal and mechanical hyperalgesia. On the other hand, morphine (an opioid) inhibited the flinch behavior and the thermal and mechanical hyperalgesia. These effects of morphine on pain-like behavior were prevented by naloxone (an opioid receptor antagonist) treatment. None of the treatments affected paw edema/tumor growth. The results showed that, in addition to tumor growth, administration of the Ehrlich tumor cells may represent a novel model for the study of cancer pain, specially the pain that is susceptible to treatment with opioids, but not to cyclooxygenase inhibitor or to tricyclic antidepressant.


Subject(s)
Behavior, Animal , Carcinoma, Ehrlich Tumor/drug therapy , Carcinoma, Ehrlich Tumor/physiopathology , Drug Evaluation, Preclinical , Pain/drug therapy , Pain/physiopathology , Amitriptyline/pharmacology , Amitriptyline/therapeutic use , Animals , Behavior, Animal/drug effects , Carcinoma, Ehrlich Tumor/complications , Carcinoma, Ehrlich Tumor/pathology , Cell Proliferation/drug effects , Disease Models, Animal , Edema/complications , Edema/drug therapy , Edema/pathology , Hyperalgesia/pathology , Hyperalgesia/physiopathology , Indomethacin/pharmacology , Indomethacin/therapeutic use , Male , Mice , Morphine/pharmacology , Morphine/therapeutic use , Neoplasm Transplantation , Nociception/drug effects , Pain/etiology , Subcutaneous Tissue/pathology , Temperature
11.
Semina cienc. biol. saude ; 33(1): 111-122, jan.-jun. 2012.
Article in Portuguese | LILACS | ID: lil-678671

ABSTRACT

O vírus do papiloma humano (HPV-human papiloma virus) pode infectar até 80% das pessoas, principalmente as sexualmente ativas. O risco e a sintomatologia da infecção são distintos entre os gêneros. Sabe-se que existem mais de 150 sorotipos e estes são agrupados por seu tropismo. Embora a maioria das infecções siga um curso benigno, a infecção persistente por certos sorotipos pode levar ao desenvolvimento de câncer. Os sorotipos 16 e 18 estão envolvidos com uma forma grave de lesão, acarretando câncer, principalmente do colo do útero. Os sorotipos 6 e 11 são descritos como causadores de verrugas anogenitais. O vírus, de aproximadamente 8.000 pb, se instala na célula e por meio da expressão das oncoproteínas E6 e E7, levando à inibição de proteínas como a p53 e a pRB, importantes na apoptose e na parada do ciclo celular. As vacinas atuais geram imunidade contra os sorotipos 6, 11, 16 e 18. A vacina pode ser tetravalente (quatro sorotipos: 6, 11, 16 e 18) ou bivalente (16 e 18). Ambas apresentam proteção cruzada contra a infecção por sorotipos não inclusos nas vacinas, porém não possuem caráter terapêutico. O presente trabalho teve como proposta revisar os avanços sobre a infecção pelo HPV, os aspectos imunológicos e as vacinas profiláticas disponíveis.


The human papilloma virus (HPV-human papilloma virus) can infect up to 80% of people, especially sexually active. The risk of infection and symptoms are different between the sexes. It is known that there are over 150 serotypes and these are grouped by their tropism. Although most infections follow a benign course, the persistent infection with certain serotypes may lead to the development of cancer. The serotypes 16 and 18 are involved in a severe form of injury, resulting in cancer, particularly cervical cancer. Serotypes 6 and 11 are described as causes of anogenital warts. The virus, approximately 8.000 bp, it installs itself in the cell and through the expression of oncoproteins E6 and E7 leading to inhibition of proteins such as p53 and pRB, important in apoptosis and cell cycle arrest. Current vaccines generate immunity against serotypes 6, 11, 16 and 18. The vaccine can be tetravalent (four serotypes 6, 11, 16 and 18) or bivalent (16, 18). Both have cross-protection against infection by serotypes not included in the vaccines, but have no therapeutic character. This study was proposed to review progress on the HPV infection, the immunological aspects and prophylactic vaccines available.


Subject(s)
Uterine Cervical Neoplasms , Papillomavirus Vaccines
SELECTION OF CITATIONS
SEARCH DETAIL
...